Background Vaccines that are shelf stable and easy to administer are crucial to improve vaccine access and reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission around the world. Methods In this study, we demonstrate that an oral, adenovirus-based vaccine candidate protects against SARS-CoV-2 in a Syrian hamster challenge model. Results Hamsters administered 2 doses of VXA-CoV2-1 showed a reduction in weight loss and lung pathology and had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G, and neutralizing antibodies were induced upon oral immunization with the sera, demonstrating neutralizing activity. Conclusions Overall, these data demonstrate the ability of oral vaccine candidate VXA-CoV2-1 to provide protection against SARS-CoV-2 disease.

中文翻译：

---

在叙利亚仓鼠挑战模型中，口服疫苗可预防严重急性呼吸系统综合症冠状病毒 2

背景 货架稳定且易于管理的疫苗对于改善疫苗获取和减少严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 在世界范围内的传播至关重要。方法 在这项研究中，我们证明了一种口服的、基于腺病毒的候选疫苗可以在叙利亚仓鼠挑战模型中预防 SARS-CoV-2。结果 给予 2 剂 VXA-CoV2-1 的仓鼠表现出体重减轻和肺部病变的减轻，并在攻击后 5 天完全消除了传染性病毒。口服免疫诱导抗尖峰免疫球蛋白G，并且在用血清口服免疫后诱导中和抗体，显示出中和活性。结论 总体而言，这些数据表明口服候选疫苗 VXA-CoV2-1 能够提供针对 SARS-CoV-2 疾病的保护。